[REVISION HISTORY]

US FDA COVID-19 vaccine updates

Updated 1 time since CLSTR started tracking revisions of this situation.

What changed

2026-09-01 14:04 UTC → 2026-09-07 13:43 UTC · added ~~removed~~

The U.S. Food and Drug Administration (FDA) has approved updated COVID-19 vaccines for the 2026-2027 season to target the XFG subvariant of the JN.1 coronavirus lineage. The approved vaccines include mRNA formulations from Moderna and Pfizer-BioNTech, alongside a protein-based option from Novavax-Sanofi. Eligibility for these updated shots is restricted to specific populations, including all adults aged 65 and older and individuals aged 5 to 64 with underlying health conditions—such as asthma, diabetes, obesity, or heart disease—that increase the risk of severe illness. These approvals occur amidst a shift in federal health policy under the Trump administration and Health and Human Services Secretary Robert F. Kennedy Jr., moving away from universal vaccine recommendations toward more restricted, individual-based decision-making. This policy change, coupled with legal challenges regarding vaccine advisory panel appointments, has prompted questions concerning insurance coverage and access for those not meeting high-risk criteria. As of September 2026, the Centers for Disease Control and Prevention (CDC) reports rising COVID-19 activity across 47 U.S. states, with particularly high viral activity noted in Alaska, Hawaii, Nevada, Texas, and Utah. While overall respiratory activity remains low, health officials attribute the upward trend to the end of summer and the start of the school year. In response, authorities are urging high-risk groups—including seniors, pregnant individuals, and those with chronic conditions—to stay updated with vaccinations and practice improved hygiene and ventilation.

Versions

Only revisions since CLSTR began indexing content versions appear here. Select a version to see what changed compared to the one before it.